



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

**MINUTES OF THE MEETING HELD ON WEDNESDAY 20TH NOVEMBER 2019
AT 12.30pm**

**IN SEMINAR ROOM 5, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T McKenzie	GP EL CCG
Mr N Fletcher (NF)	Director of Pharmacy ELHT

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
Ms W Lyons	Specialist Nurse, Medicines Management, EL CCG
Ms P Harris	Matron, Community

2019/153: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

2019/154: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2019/155: MINUTES OF OCTOBER MEETING:

Item 142 Guideline for Antihyperglycaemic therapy in type 2 Diabetes updated. Amend to - comments have been sent back for CCGs separately.

Otherwise accepted as a correct record.

2019/156: MATTERS ARISING:

2019/064: Formulary Updates - Tranexamic acid injection for topical use

An amended version was presented as paper copy at the meeting which was approved for use. Tranexamic acid injection for topical use traffic light to be changed to green.

Traffic light: GREEN

2019/093: New Product Request – Lanreotide – item closed, refer to LMMG consultation on main agenda.

2019/095: New Product Request – Parathyroid hormone (Natpar®) - NF to attain clarity over whether ELHT is a specialist centre and can claim for Natpar from NHSE.

2019/106: Hospital Admissions Checklist – Updated – ongoing, LR has meeting with care home team arranged.

2019/131: Treatment of Vitamin B12 Deficiency Draft – LR has met with biochemist to agree pathway in line with local thresholds. The pathway is to be brought to ELMMB when completed.

2019/143: LMMG Recommendations (From Sept LMMG) - ADHD Shared Care Guideline – updated - VG is meeting with paediatric pharmacist and will feed back concerning compliance with shared care at next meeting.

2019/157: WOUND CARE FORMULARY - UPDATE

Wendy Lyons in attendance for this item. The wound care formulary has been updated to include only wound care dressings. More specialist products such as lymphoedema products have been omitted and will be reviewed separately. Some items have been replaced with more cost effective options in closer alignment with the rest of Lancashire. The district nurse request forms will be updated to contain the updated items.

Resolved: Updated Wound care Formulary acknowledged.

2019/158: NEW PRODUCT REQUEST – NAVINA®

Polly Harris in attendance for this item. Navina® is a trans anal irrigation product that offers benefit to a niche group of patients for whom the other available products are less suitable. It would only be used under the supervision of the bladder and bowel continence team. It was agreed to include on the formulary with the other trans anal products.

Resolved: Navina® added to formulary for use by continence service only.

Traffic light: AMBER

2019/159: NEW PRODUCT REQUEST – ARTESUNATE INJECTION

Requested by microbiology as it is the recommended treatment in national guidelines for severe malaria caused by Plasmodium Falciparum. It was agreed to include on formulary for use only under supervision of a microbiologist.

Resolved: Artesunate be added to formulary under microbiology recommendation only.

Traffic light: RED

2019/160: NEW UNLICENSED PRODUCT REQUEST – HUMAN CHORIONIC GONADOTROPHIN (GONASI®)

Requested by Dr Baig, Consultant Endocrinologist, for treatment of hypogonadotropic hypogonadism. It is recommended in guidance for this indication. It was agreed to include on formulary for use by endocrinologists only.

Resolved: Human chorionic gonadotrophin (Gonasi®) be added to formulary for endocrinology use only.
Traffic light: RED

2019/161: NEW PRODUCT REQUEST – CEFTOLOZANE/TAZOBACTAM

Requested by microbiology for the treatment of multi drug resistant infections or as part of therapy for licensed indications. It would be on microbiology advice only when treatment choices are limited and not included on susceptible/resistance reports. It was agreed to include on formulary for microbiology use only.

Resolved: Ceftolozane/Tazobactam be added to formulary for microbiology recommendation only.
Traffic light: RED

2019/162: LSCMMG CONSULTATIONS (for Dec LSCMMG)

Azathioprine in Myasthenia Gravis New Medicines Assessment – supported. Recommend it is included on shared care agreement when approved.

Octreotide /Lanreotide for GI bleeding New Medicine Assessment – supported. Recommend including that anticoagulants/ antiplatelets have been stopped if this is appropriate before this treatment is considered.

Cyanocobalamin New Medicines Assessment – supported but suggest that separate indications don't need to be listed – just needs to recommend Black for all to avoid potential confusion.

Self-Care & Homely Remedy Template Policy – concern that it involves GP's signing for everything, and ELHE already has a more suitable policy that has been previously approved. Concerns were also expressed with the inclusion of loperamide for diarrhoea without some initial questions to rule out inappropriate use. Comments to be submitted. ELMMB supported use of existing policy.

Resolved: Comments to be sent to LMMG

2019/163: LSCMMG Recommendations (From Oct LSCMMG)

Lithium Shared Care Guideline (updated June) – it now includes calcium monitoring and is accepted as written for ELHE.

Question raised - should the GP be informed of the individual target levels as stated in section 3 on page 2.

Action: LR to follow up with LCFT.

Suliqua® (Insulin Glargine/Lixisenatide) New Medicine Recommendation – request submitted from BwD CCG. LSCMMG recommendation challenged with a request to review locally. The information received reflected that considered by LSCMMG. It was agreed to accept the LSCMMG recommendation as written with a black traffic light.

Traffic light: BLACK

Liothyronine New Medicine Recommendation – it is in line with current local accepted recommendations. VG to check with endocrinologists if the third bullet point under secondary care prescribing can be removed.

Action: VG to follow up with endocrinologists.

2019/164: FORMULARY UPDATES

Famotidine tablets – alternative to ranitidine while there are supply issues, if omeprazole/ lansoprazole is not appropriate.

Rosuvastatin – already included on formulary at previous meeting.

Ensure & Fresubin original – to be removed from formulary, no longer used.

Febuxostat – following drug safety alert to change traffic light from green to Amber

Traffic Light: AMBER

Testosterone gel (Testavan®) – to be added to formulary. It is already included in the shared care guidelines for testosterone.

Traffic Light: AMBER

Hydrocortisone Emergency Injection Kit – for emergency use in adrenal crisis in patients with adrenal insufficiency. Pack contains the hydrocortisone and diluent, needles, syringes, wipes and information leaflet. Added to formulary. **Traffic Light: RED**

Resolved: Formulary to be updated as above

2019/165: ELHT: ADULT ANTIMICROBIAL GUIDE

Daptomycin Dosing and Monitoring advice - added

Resolved: Daptomycin section of Adult Antimicrobial Guide acknowledged.

2019/166: MEPOLIZUMAB SHARED CARE AGREEMENT FORMS

Agreement to transfer the care of Lancashire teaching Hospitals patients to East Lancs for this NHSE commissioned treatment acknowledged.

Resolved: Mepolizumab shared care agreement forms acknowledged.

2019/167: QUININE PATIENT INFORMATION LEAFLET

Leaflet to support self-care of leg cramps. Add regular walking to suggestions for self-help, then upload to website

Action: Treatment of Leg Cramps PIL to support self-care acknowledged.

2019/168: NICE RECOMMENDATIONS (from Oct)

Idelalisib for treating refractory follicular lymphoma [TA604] is not recommended as an option by NICE. **Traffic Light: BLACK**

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea [TA605] is recommended as an option by NICE. Approved in line with NICE. CCG Commissioned – Blue Teq form required **Traffic Light: RED**

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606) is recommended as an option by NICE. Approved in line with NICE. **Traffic Light: RED**

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607) is recommended as an option by NICE. Approved in line with NICE. CCG Commissioned **Traffic Light: RED**

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608) **Traffic Light: BLACK**

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609). **Traffic Light: BLACK**

2019/169: HIGHLY SPECIALISED TECHNOLOGIES GUIDANCE (from Oct)

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST 11) is recommended. Acknowledged

STANDING ITEMS

2019/170: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES - October 2019
Minutes acknowledged

2019/171: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – September 2019

Minutes acknowledged

Comments from KB:

Antimicrobial Stewardship week this week – please sign up to on website

Work on CQUINs is continuing

Withdrawal of urine dip sticks in trust is going well with a decrease in trimethoprim and nitrofurantoin prescribing.

ELMMB would like to thank Dr Kirsty Burch, on her retirement, for her valuable contributions to the committee.

DATE OF NEXT MEETING – Wednesday 18th December 2019 12.30pm, Pharmacy Seminar Room, Pharmacy Department, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 20TH NOVEMBER 2019

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/096	New Product request Parathyroid Hormone (Natpar®) – check with finance and NHSE if the ELHT endocrinology is considered to be ‘specialist endocrinology’ for reimbursement of drug expenses	NF	Nov 19
2019/106	Hospital Admissions Checklist – Updated – share with CCG Care Home Team and provide feedback.	LR	Oct 19
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed	LR/JV	Dec 19
2019/143	ADHD Shared Care Guideline Follow up the compliance with shared care with paediatric pharmacist	VG	Nov 19
2019/163	LSCMMG Recommendations (From Oct LSCMMG) Lithium Shared Care Guideline (updated June) – Should GPs be informed of individual target levels as stated in section 3 on page 2, to follow up with LCFT.	LR	Dec 19
2019/163	LSCMMG Recommendations (From Oct LSCMMG) - Liothyronine New Medicine Recommendation – check with endocrinologists if 3 rd bullet point in secondary care section can be removed	VG	Dec 19